12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Increlex mecasermin: Phase I/II started

The Boston Children's Hospital began a U.S. Phase I/II trial in 40 female patients ages 2-12 to evaluate subcutaneous Increlex. The dose-escalation Phase I portion will evaluate twice-daily 40, 80 and 120...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >